What is Wedbush's Estimate for Replimune Group Q3 Earnings?

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Equities researchers at Wedbush lifted their Q3 2025 earnings per share (EPS) estimates for Replimune Group in a note issued to investors on Tuesday, November 12th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.68) per share for the quarter, up from their prior estimate of ($0.80). The consensus estimate for Replimune Group's current full-year earnings is ($3.05) per share. Wedbush also issued estimates for Replimune Group's Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.10) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($3.28) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($2.08) EPS and FY2029 earnings at ($1.38) EPS.

A number of other equities analysts have also issued reports on the company. Roth Capital raised Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. Roth Mkm began coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 24th. Finally, HC Wainwright restated a "buy" rating and set a $17.00 target price on shares of Replimune Group in a report on Tuesday. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Replimune Group currently has an average rating of "Buy" and a consensus target price of $16.80.

Replimune Group Stock Down 5.5 %

NASDAQ:REPL traded down $0.63 during trading hours on Friday, hitting $10.77. The company's stock had a trading volume of 336,307 shares, compared to its average volume of 1,032,731. The stock has a market capitalization of $736.88 million, a P/E ratio of -3.74 and a beta of 1.19. The stock has a fifty day moving average of $11.44 and a 200-day moving average of $9.50. The company has a current ratio of 10.11, a quick ratio of 13.46 and a debt-to-equity ratio of 0.18. Replimune Group has a 52-week low of $4.92 and a 52-week high of $12.97.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07.

Institutional Trading of Replimune Group

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC raised its holdings in shares of Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company's stock worth $122,000 after purchasing an additional 3,150 shares during the period. Algert Global LLC increased its position in shares of Replimune Group by 5.4% in the second quarter. Algert Global LLC now owns 84,033 shares of the company's stock worth $756,000 after acquiring an additional 4,340 shares in the last quarter. Creative Planning increased its position in shares of Replimune Group by 28.7% in the third quarter. Creative Planning now owns 21,047 shares of the company's stock worth $231,000 after acquiring an additional 4,699 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock worth $45,000 after acquiring an additional 4,946 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its position in shares of Replimune Group by 8.1% in the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company's stock worth $646,000 after acquiring an additional 5,410 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.